CAS 107021-36-3

PRAZOBIND

Description:

PRAZOBIND, with the CAS number 107021-36-3, is a specific antidote used for reversing the effects of the anticoagulant drug dabigatran, which is a direct thrombin inhibitor. It is a monoclonal antibody fragment designed to bind specifically to dabigatran and its active metabolites, thereby neutralizing their anticoagulant effects. PRAZOBIND is administered intravenously and is indicated in situations where rapid reversal of dabigatran is necessary, such as in cases of major bleeding or prior to emergency surgery. The substance is characterized by its high affinity for dabigatran, allowing for effective binding and neutralization. Its pharmacokinetics involve a rapid onset of action, with effects typically observed shortly after administration. PRAZOBIND is generally well-tolerated, but like any medical intervention, it may have potential side effects, which should be monitored by healthcare professionals. Overall, PRAZOBIND represents a significant advancement in the management of patients on dabigatran therapy, providing a critical tool for ensuring patient safety in emergency situations.

Formula: C₂₃H₂₇N₅O₃

InChI: InChI=1/C23H27N5O3/c1-30-19-12-17-18(13-20(19)31-2)25-23(26-21(17)24)28-9-7-27(8-10-28)22(29)16-11-14-3-5-15(16)6-4-14/h3,5,11-15H,4,6-10H2,1-2H3,(H2,24,25,26)

SMILES: COc1cc2c(cc1OC)nc([nH]c2=N)N1CCN(CC1)C(=O)C1=CC2C=CC1CC2

Synonyms:

• 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-bicyclo[2.2.2]octa-2,5-dienyl-carbonyl)-piperazine
• Szl-4
• Szl 49
• SZL-49, 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-bicyclo[2,2,2]octa-2,5-dienyl-carbonyl)-piperazine
• [4-(4-Amino-6,7-Dimethoxyquinazolin-2-Yl)Piperazin-1-Yl](Bicyclo[2.2.2]Octa-2,5-Dien-2-Yl)Methanone

Prazobind

CAS: 107021-36-3

Prazobind is a prazosinoid substance that blocks insulin stimulation of IP1 (inositol phosphate) accumulation and is an effective α1 adrenoceptor blocker.

Formula: C₂₃H₂₇N₅O₃

Color and Shape: Solid

Molecular weight: 421.501

Ref: TM-T35581

Prazobind

CAS: 107021-36-3

Prazobind is an irreversible inhibitor of the enzyme phosphodiesterase 3. This drug inhibits the degradation of cyclic AMP, which leads to increased intracellular levels of Ca2+. Prazobind has been shown to have a beneficial effect on liver cells and phenoxybenzamine-induced hypertension in rats. The kinetic data obtained from polymerase chain reaction studies show that Prazobind has a high affinity for polymerase enzymes with a low dissociation constant. This drug also inhibits transcription and replication by binding to the active site of RNA polymerase. It also produces an increase in proximal tubule Ca2+ influx and glomerular filtration rate in rats, which may be due to reactive functional groups present in the drug.

Formula: C₂₃H₂₇N₅O₃

Purity: Min. 95%

Color and Shape: White to off-white solid.

Molecular weight: 421.49 g/mol

Ref: 3D-FP27127

Prazobind

Controlled Product

CAS: 107021-36-3

Stability -200C
Applications α1-Adrenoceptor alkylating reagent. A Prazosin analog. An antihypertensive.
References Piascik, M.T., et al.: J. Pharmacol. Exp. Ther., 251, 878 (1989), Pitha, J., et al.: J. Med. Chem., 32, 96 (1989), Mante, S., et al.: Eur. J. Pharmacol., 208, 113 (1991),

Formula: C₂₃H₂₇N₅O₃

Color and Shape: Neat

Molecular weight: 421.49

Ref: TR-P702150